Drugs in ATC Class N05CA

Up to Top Level ATC Classes

Up to N - Nervous system

Up to N05 - PSYCHOLEPTICS

Up to N05C - HYPNOTICS AND SEDATIVES

Drugs in ATC Class: N05CA - Barbiturates, plain

Tradename	Generic Name
NEMBUTAL	pentobarbital
NEMBUTAL SODIUM	pentobarbital sodium
PENTOBARBITAL SODIUM	pentobarbital sodium
SODIUM PENTOBARBITAL	pentobarbital sodium
NEMBUTAL	pentobarbital sodium
BUTICAPS	butabarbital sodium

Market dynamics and patent landscape for ATC Class N05CA: Barbiturates (plain)

Last updated: June 9, 2026

ATC N05CA barbiturates (plain) is a mature, largely generic market with limited patent-driven differentiation. Market access is driven more by FDA/ANDA/505(j) and state-level controlled-substance requirements than by long-running exclusivity. Patent leverage, where it exists, is concentrated in legacy compositions and process improvements, not broad brand-style exclusivity across the class.

The N05CA umbrella covers multiple barbiturates used primarily for sedative-hypnotic and anticonvulsant indications. Because most products are off-patent and widely marketed, the competitive baseline is price compression, supply-chain reliability, and DEA scheduling compliance. Where “plain” barbiturates are involved, switching and therapeutic substitution are usually commercially feasible, further reducing the value of incremental formulation patents.

Which barbiturates fall under ATC N05CA and how do their market dynamics differ by product?

N05CA is the ATC category for barbiturates, plain. The category spans different active ingredients with distinct clinical use patterns (e.g., phenobarbital for epilepsy vs. pentobarbital/thiopental for procedural or institutional use where available). In practice, market dynamics vary less by ATC coding and more by:

• formulation availability (oral vs. injectable)
• DEA schedule handling and institutional procurement
• patent status at the active ingredient and dosage form level
• supply continuity (sterility, sterile injectable capacity, and controlled substance logistics)

What are the typical product forms and buyers for N05CA plain barbiturates?

• Oral tablets/capsules for chronic or ambulatory use (notably phenobarbital-based regimens where still used).
• Oral solutions/elixirs for pediatric or titration use where formularies support them.
• Injectable products for inpatient and institutional procurement (where specific actives are used).

Buyer profiles:

• hospital and health system pharmacy procurement
• specialty pharmacies for chronic neurology patients
• institutional procurement channels for controlled-substance injectables

How does generic competition affect pricing and volume in barbiturates?

• With broad generic entry, pricing typically trends toward the marginal-cost floor for each dosage form.
• Volume stability is usually supported by entrenched clinical practice in certain indications (most notably phenobarbital in some epilepsy contexts), but share can shift based on acquisition cost, formulary decisions, and supply reliability.
• Barbiturate supply disruptions can temporarily improve pricing, but they usually attract rapid follow-on demand from competing generic manufacturers once supply normalizes.

What patents protect barbiturates (plain) in ATC N05CA, and how is patent coverage structured?

Patent landscapes for barbiturates are generally “thin” at the class level and fragmented at the ingredient and dosage-form level. Coverage commonly includes one or more of the following:

1. historical composition of matter (rarely still enforceable for older actives)
2. historical method of preparation (process patents are harder to enforce but can still matter in some jurisdictions)
3. formulation-specific IP (e.g., controlled-release, improved solubility, or sterile manufacturing methods)
4. method-of-use patents tied to dosing regimens or new indications (less common for widely used barbiturates)

How many patents cover ATC N05CA barbiturates, plain?

For many barbiturates, the effective patent count is low because most “core” patents have expired. Remaining enforceability is usually limited to:

• specific dosage forms
• specific manufacturing steps or validation approaches
• narrow regulatory exclusivity remnants, where applicable

Which patent holders typically appear in the barbiturate landscape?

Where patents still appear, assignees tend to cluster around:

• legacy brand-origin companies that developed the active ingredient formulations
• generic manufacturers that acquired legacy portfolios
• small specialty pharma entities with narrow process or formulation patents

In this market segment, the most commercially meaningful IP is often not broad composition coverage but rather the regulatory and manufacturing “workarounds” that are required to obtain ANDA approval or to pass patents listed in Orange Book for a specific NDC.

What does patent coverage mean for generics?

For generics, the operational impact is primarily:

• whether an ANDA applicant must file Paragraph IV certifications to listed patents
• whether litigation leads to a 30-month stay
• whether a settlement agreement narrows the design space for launch timing

Because class-level patents are uncommon, launch risk is evaluated per NDC, per dosage form, per listed patent family, and per jurisdiction.

When does N05CA barbiturate exclusivity end, and how do patent expirations map to generic launch timing?

For ATC N05CA, exclusivity is usually not a single end date. The practical launch timeline is a function of multiple triggers:

• patent expiration (composition, formulation, or process patents)
• regulatory exclusivity (e.g., orphan drug, if any active ingredient/indication is still under such a program, though this is not typical for the plain barbiturate category)
• FDA approval pathway timing and 505(b)(2)/505(j) dependencies
• settlement terms if Paragraph IV litigation occurred

What is the typical timeline to generic entry after patents expire?

A generic launch often follows:

1. ANDA filing with Paragraph IV if patents are listed
2. FDA acceptance and certification notification
3. litigation window and possible 30-month stay under the Hatch-Waxman framework
4. resolution by dismissal, trial outcomes, or settlement design
5. FDA approval and commercial launch soon after

How often do settlements drive “at-risk” barbiturate launches?

More than in premium therapeutics, settlements in barbiturate generics tend to:

• lock in a launch date at the NDC level
• require changes to manufacturing or labeling language
• define which patent numbers are “resolved” and which remain at issue

What patent litigation affects barbiturates (plain) and what are the common outcomes?

Barbiturate litigation tends to be more transactional than precedent-setting. Common patterns:

• Paragraph IV challenges to Orange Book-listed patents for a specific dosage form
• narrow settlements that allow a generic entrant to launch at a defined time, sometimes “carving out” certain formulations or strengths

What launch blockers appear in litigation?

• listed patents covering a specific strength or dosage form
• method-of-use or dosing regimen claims tied to labeling
• manufacturing-process patents that the generic must avoid or certify

How do litigation outcomes change generic launch risk?

• A dismissal or non-infringement finding lowers launch uncertainty and enables faster commercial timelines.
• A settlement that imposes delayed launch reduces at-risk entry but preserves profitability for the generic entrant once the effective date arrives.

What is the Orange Book status of barbiturates (plain), and how many patents are listed per product?

Orange Book analysis for N05CA is product-specific. The relevant unit is the listed drug product (strength, dosage form, and active ingredient). In barbiturates:

• many products have no enforceable listed patents
• remaining listings, when present, are typically limited and tied to formulation or manufacturing

How do Orange Book listings differ by dosage form?

• Tablets vs. solutions vs. injectables can have different listing profiles.
• Sterile injectables can have more process-related listings.
• Oral solutions may have excipient-related formulation listings.

Which companies are challenging patents for N05CA barbiturates and what is the competitive landscape?

The competitive landscape is dominated by:

• large generic manufacturers with broad ANDA portfolios
• specialty generics that focus on niche dosage forms or supply reliability
• contract manufacturers that can support controlled-substance production and packaging

How do generic entrants position against incumbents?

• price-driven tenders to health systems
• supply assurances and continuity of supply
• regulatory readiness (ANDAs already approved or pending)
• controlled-substance compliance and logistics competence

Patent leverage determines how quickly challengers can secure “first” or “preferred” status in procurement. Where patents are absent or expired, competitors enter quickly.

How does product switching affect market share?

Substitution risk is high:

• payers and formularies often allow switching among bioequivalent generics
• for many barbiturate uses, clinical switching is feasible with appropriate monitoring
• this reduces the duration of any single entrant’s pricing advantage after generic entry

How strong is the patent estate for N05CA barbiturates, and where is remaining enforceability located?

At the category level, the estate is weak. Strength, where it exists, is concentrated in narrow claims:

• specific formulations
• specific manufacturing methods
• narrower method-of-use or labeling language

What types of claims tend to survive longer in barbiturates?

• formulation process improvements that support regulatory compliance
• sterile manufacturing validation or packaging methods where they were patented
• narrow controlled-release concepts (less typical for “plain” barbiturates but possible for select products)

What is the practical barbell: weak class-level IP but strong product-level blocking?

Even if barbiturates are mostly off-patent, product-level blocking can still occur because:

• Orange Book listings bind ANDA labeling and require certifications
• a single remaining formulation or process patent can delay one dosage form even if other strengths are free

What generic entry risks exist for N05CA barbiturates if you are developing or partnering?

Key entry risks are procedural and regulatory rather than purely patent-driven:

1. Orange Book listing exposure per NDC: a narrow patent can trigger litigation.
2. 30-month stay risk for Paragraph IV certifications: can compress or eliminate ROI.
3. Settlement constraints: could mandate design or timing restrictions.
4. Controlled-substance supply chain constraints: manufacturing capacity and DEA handling affect scaling.
5. Sterile manufacturing qualification (for injectables): increases time-to-market and change-control burden.

How do you evaluate launch risk for a specific barbiturate NDC?

• identify listed patents and their expiration dates by strength/dosage form
• check whether any Paragraph IV challenges are active in court for that exact product
• map potential settlement outcomes to an anticipated launch window
• confirm manufacturing feasibility and validation for the chosen generic design space

How do ATC N05CA barbiturates compare with other sedatives in terms of IP and competitive intensity?

Compared with modern sedative-hypnotics, barbiturates typically show:

• lower brand-like IP density
• faster generic substitution and procurement-driven pricing compression
• fewer active method-of-use innovations at scale

This makes barbiturate commercialization more dependent on:

• regulatory execution
• supply reliability
• ability to win tenders than on sustained IP monetization.

Regulatory and market access constraints: what FDA pathway issues matter for N05CA plain barbiturates?

Most market entry is through ANDA pathways where generics are allowed. Core constraints:

• FDA bioequivalence and formulation compatibility
• controlled-substance manufacturing and labeling
• changes in manufacturing sites or process require compliance with post-approval requirements
• for injectables, sterility assurance and facility readiness matter for approval and ongoing supply

What manufacturing/IP barriers block competitors in N05CA barbiturates?

Manufacturing barriers tend to be more operational than patent-based:

• sterile injectable readiness: cleanroom, aseptic process controls, and validated sterility assurance
• stability and packaging constraints: controlled-substance storage and re-test schedules
• site qualification and change control: delays for manufacturing relocations or scale-up
• excipient and process sensitivities: where specific formulations have narrower design space

If a product has narrow formulation/process patents still listed, these operational constraints can also become legal constraints because generic applicants must avoid infringing claim scope and must maintain bioequivalence.

---

Key Takeaways

• N05CA plain barbiturates are a mature, heavily generic market; patent leverage is usually fragmented and product-level, not class-wide.
• Market dynamics are driven by procurement, controlled-substance compliance, supply continuity, and per-NDC regulatory status more than by sustained exclusivity.
• Remaining enforceability, when present, is concentrated in narrow formulation/process claims that can block individual strengths or dosage forms through Orange Book listings and Paragraph IV litigation.
• Generic entry risk is mostly procedural (Orange Book certifications, 30-month stays, settlements) and operational (sterile manufacturing and controlled-substance supply execution).

---

FAQs

1) Which barbiturate dosage forms under N05CA tend to have the most persistent Orange Book listings?
Injectables and select oral formulations often show more product-specific listings because manufacturing and formulation parameters are more tightly controlled and more likely to have been patented.

2) How do Paragraph IV certifications typically change barbiturate launch timelines?
They can trigger a 30-month stay and lead to settlements that set launch dates at the specific NDC level, narrowing at-risk entry.

3) Do method-of-use patents play a meaningful role in N05CA barbiturate generic barriers?
They appear less frequently as broad, durable blockers for the category, but can matter for specific labeling-linked dosing regimens where claims exist.

4) What is the main commercial advantage for a barbiturate generic entrant when patents are expired?
Supply reliability plus procurement pricing and tender responsiveness usually determines share more than marketing or brand-like differentiation.

5) What operational factors most affect time-to-market for generic N05CA barbiturates?
Manufacturing validation, sterility assurance for injectables, stability/packaging qualification, and controlled-substance logistics readiness.

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA. Hatch-Waxman (Biologics Price Competition and Innovation Act framework for ANDAs and exclusivity provisions). U.S. Food and Drug Administration.
3. U.S. Court of Appeals for the Federal Circuit and district court decisions interpreting 35 U.S.C. § 271 and Hatch-Waxman 30-month stay mechanics (general framework reference).